NDTVCenter·
Johnson & Johnson's Prostate Cancer Drug JNJ-6143 Shrinks Tumours In Early Trial
In the early-stage trial, 77% of 31 evaluable patients receiving the 50-milligram dose experienced a PSA decline of at least 50%, while 48% recorded reductions of 90% or more.
Read at NDTV →
